<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04848220</url>
  </required_header>
  <id_info>
    <org_study_id>APD791-202</org_study_id>
    <secondary_id>2020-000238-16</secondary_id>
    <nct_id>NCT04848220</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Effect on Microvascular Obstruction of Temanogrel in Subjects Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intravenous temanogrel is a safe and&#xD;
      effective treatment for microvascular obstruction (MVO) in adult participants undergoing&#xD;
      percutaneous coronary intervention (PCI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to be&#xD;
      conducted in 2 stages (Stage A and Stage B). Stage A is an ascending single-dose&#xD;
      placebo-controlled study planned to consist of 2 cohorts. Stage B is a parallel-treatment&#xD;
      group study planned to consist of a placebo group and 2 active treatment groups of temanogrel&#xD;
      doses selected based on safety and tolerability data in Stage A.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Index of Microcirculatory Resistance (IMR) From Baseline to Post-Percutaneous Coronary Intervention (PCI)</measure>
    <time_frame>Baseline (prior to administration of study treatment) to Post-PCI on Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Post-PCI for Other Coronary Physiology Indices</measure>
    <time_frame>Baseline (prior to administration of study treatment) to Post-PCI on Day 1</time_frame>
    <description>Coronary physiology indices include coronary flow reserve (CFR) and fractional flow reserve (FFR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Post-PCI for Angiographic Measures</measure>
    <time_frame>Baseline (prior to administration of study treatment) to Post-PCI on Day 1</time_frame>
    <description>The analysis of the target vessel angiographic measures include corrected thrombolysis in myocardial infarction frame count (cTFC), thrombolysis in myocardial infarction flow grade (TFG), and thrombolysis in myocardial infarction myocardial perfusion grade (TMPG).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Post-PCI for Myocardial Injury Markers</measure>
    <time_frame>Baseline (prior to administration of study treatment) to Post-PCI on Day 1</time_frame>
    <description>Myocardial injury markers include creatine kinase (CK), creatine kinase-myocardial band (CK-MB), and cardiac troponin (cTn).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Procedural Myocardial Injury</measure>
    <time_frame>Baseline (prior to administration of study treatment) and at 6 and 24 hours Post-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Plasma Concentration (Cmax) of Temanogrel and Active Metabolites AR295980 and AR295981</measure>
    <time_frame>Baseline (prior to administration of study treatment); Pre-PCI; and at 1, 3, 6 and 24 hours Post-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Severity of Adverse Events</measure>
    <time_frame>Study Day 1 through Study Day 8</time_frame>
    <description>Safety will be assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Microvascular Obstruction</condition>
  <arm_group>
    <arm_group_label>Stage A (Dose Cohort 1) and Stage B (Dose Group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage A (Dose Cohort 2) and Stage B (Dose Group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage A (Dose Cohort 1 and Dose Cohort 2) and Stage B (Dose Group 1 and Dose Group 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temanogrel</intervention_name>
    <description>Participants will receive a single intravenous dose of temanogrel on Day 1</description>
    <arm_group_label>Stage A (Dose Cohort 1) and Stage B (Dose Group 1)</arm_group_label>
    <arm_group_label>Stage A (Dose Cohort 2) and Stage B (Dose Group 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive a single intravenous dose of temanogrel matching placebo on Day 1</description>
    <arm_group_label>Stage A (Dose Cohort 1 and Dose Cohort 2) and Stage B (Dose Group 1 and Dose Group 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stable angina patients referred for elective percutaneous coronary intervention (PCI),&#xD;
             or non-ST-elevation myocardial infarction (NSTEMI) and unstable angina (UA) patients&#xD;
             (undergoing PCI at least 12 hours after diagnosis for NSTEMI/UA, consistently&#xD;
             hemodynamically stable, with thrombolysis in myocardial infarction (TIMI) Flow Grade&#xD;
             (TFG) 3 on the diagnostic angiography)&#xD;
&#xD;
          -  Target lesions for PCI must appear suitable for stenting as confirmed on the&#xD;
             diagnostic angiography and must satisfy the study criteria regarding lesion size and&#xD;
             vessel diameter/type&#xD;
&#xD;
          -  Females must not be of childbearing potential&#xD;
&#xD;
          -  Males with pregnant or non-pregnant female partners of childbearing potential must&#xD;
             agree to using a condom during treatment and for 90 days following treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planned or anticipated use of rotational atherectomy/ablation or shockwave therapies&#xD;
             during the PCI procedure&#xD;
&#xD;
          -  Any history of stroke, head injury, seizure, intracranial bleeding, or intracranial&#xD;
             aneurysm&#xD;
&#xD;
          -  Transient ischemic attack within the 6 months prior to Screening&#xD;
&#xD;
          -  History of major trauma, major surgery, and/or clinically significant hemorrhage&#xD;
             within the last 6 months of Screening&#xD;
&#xD;
          -  NSTEMI/UA with cardiac troponin (cTn) levels that are increasing (not stable or&#xD;
             dropping) as shown by the 2 most recent measures after diagnosis of NSTEMI/UA and&#xD;
             prior to randomization&#xD;
&#xD;
          -  Any ST-elevation myocardial infarction (STEMI) within 10 days of Screening or STEMI&#xD;
             within the target vessel territory within the last 6 months of Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arena CT.gov Administrator</last_name>
    <role>Study Director</role>
    <affiliation>Arena Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arena CT.gov Administrator</last_name>
    <phone>+1 855-218-9153</phone>
    <email>ct.gov@arenapharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA Palo Alto - Cardiac Catheterization Laboratory</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maasstad Hospital</name>
      <address>
        <city>Rotterdam</city>
        <state>South Holland</state>
        <zip>3079 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sk√•ne University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>East and North Hertfordshire NHS Trust Lister Hospital</name>
      <address>
        <city>Stevenage</city>
        <zip>SG1 4AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Temanogrel</keyword>
  <keyword>Microvascular obstruction</keyword>
  <keyword>APD791</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>MVO</keyword>
  <keyword>PCI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>APD791</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

